Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fluorometholone
Drug ID BADD_D00929
Description A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)
Indications and Usage For the ophthalmic treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
Marketing Status approved; investigational
ATC Code C05AA06; D07AB06; D07XB04; D10AA01; S01BA07; S01CB05
DrugBank ID DB00324
KEGG ID D01367
MeSH ID D005469
PubChem ID 9878
TTD Drug ID D0P0HT
NDC Product Code 22552-0050; 60758-880; 82298-119; 46439-8770; 82298-120; 11980-211; 11980-228
UNII SV0CSG527L
Synonyms Fluorometholone | FML Liquifilm | PMS-Fluorometholone | PMS Fluorometholone | Cortisdin | Efflumidex | FML Forte | Flucon | Isopto Flucon | Flucon, Isopto | Fluor-Op | Fluor Op | Fluoro-Ophtal | Fluoro Ophtal | Fluoropos | FML
Chemical Information
Molecular Formula C22H29FO4
CAS Registry Number 426-13-1
SMILES CC1CC2C3CCC(C3(CC(C2(C4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Impaired healing08.03.02.001--Not Available
Instillation site pain12.07.01.008; 08.02.01.0080.000824%Not Available
Intraocular pressure increased13.07.04.002--Not Available
Iridocyclitis06.04.03.001--Not Available
Keratitis06.04.02.002--
Lacrimation increased06.08.02.004--
Mydriasis06.05.03.004; 17.02.11.003--Not Available
Ocular hyperaemia06.04.05.0040.000375%Not Available
Optic nerve injury06.11.02.001; 17.04.05.008; 12.01.16.001--Not Available
Pain08.01.08.0040.002099%
Rash23.03.13.001--Not Available
Toxic epidermal necrolysis12.03.01.015; 11.07.01.006; 10.01.01.006; 23.03.01.008--
Uveitis10.02.01.023; 06.04.03.003--
Viral infection11.05.04.001--Not Available
Vision blurred06.02.06.007; 17.17.01.0100.001012%
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Visual impairment06.02.10.013--Not Available
Foreign body sensation in eyes06.01.01.006--Not Available
Conjunctival hyperaemia06.04.01.004--Not Available
Eye pruritus06.04.05.0060.001274%Not Available
Ocular discomfort06.08.03.008--Not Available
Nerve injury17.02.10.007; 12.01.12.002--Not Available
Drug resistance08.06.01.0050.000562%Not Available
Sensation of foreign body08.01.09.002--Not Available
Corneal infection11.01.06.005; 06.04.02.007--
Ulcerative keratitis10.02.01.021; 06.04.02.004--
Treatment failure08.06.01.0170.001911%Not Available
Open globe injury12.01.04.016; 06.11.01.008--Not Available
Dellen06.06.03.0220.000375%Not Available
The 2th Page    First    Pre   2    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene